Please contact our sales representative to learn more information about this reagents.
Background
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a. Sifalimumab was developed by MedImmune, as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.